Gene therapy's promise for treating rare diseases faces a critical safety hurdle that this research helps explain. When clinical trials for X-linked myotubular myopathy unexpectedly resulted in fatal liver injuries—complications that preclinical testing had failed to predict—researchers needed to understand why their mouse models missed this devastating side effect.
The investigation reveals a "multi-hit" mechanism where genetic deficiency, dietary composition, and viral gene delivery converge to trigger liver damage. Mice lacking the MTM1 gene developed cholestatic liver disease only when fed purified ingredient diets, exhibiting elevated liver enzymes, altered bile acid profiles, and structural damage mirroring human patients. The MTM1 protein appears essential for maintaining hepatocyte architecture and proper positioning of bile transport machinery. When researchers combined this dietary sensitization with AAV8 viral gene therapy, liver toxicity increased dramatically in knockout mice and even appeared in normal mice.
This finding challenges the standard preclinical testing paradigm, which typically uses standard laboratory chow rather than processed diets that might better reflect human nutritional patterns. The research suggests that environmental factors like diet composition can unmask genetic vulnerabilities that remain hidden under conventional testing conditions. The successful prevention of liver abnormalities using lipid nanoparticle delivery instead of viral vectors offers a potential path forward. For the gene therapy field, this work underscores the need for more sophisticated preclinical models that account for gene-environment interactions, particularly as therapies move toward treating complex genetic disorders where multiple biological systems intersect.